Jack A. Khattar
Net Worth
Last updated:
What is Jack A. Khattar net worth?
The estimated net worth of Mr. Jack A. Khattar is at least $78,989,746 as of 8 Nov 2024. He owns shares worth $38,130,501 as insider, has earned $19,019,245 from insider trading and has received compensation worth at least $21,840,000 in Supernus Pharmaceuticals, Inc..
What is the salary of Jack A. Khattar?
Mr. Jack A. Khattar salary is $1,680,000 per year as Founder, Pres, Chief Executive Officer, Sec. & Director in Supernus Pharmaceuticals, Inc..
How old is Jack A. Khattar?
Mr. Jack A. Khattar is 64 years old, born in 1961.
What stocks does Jack A. Khattar currently own?
As insider, Mr. Jack A. Khattar owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | Founder, Pres, Chief Executive Officer, Sec. & Director | 926,172 | $41.17 | $38,130,501 |
What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Jack A. Khattar insider trading
Supernus Pharmaceuticals, Inc.
Mr. Jack A. Khattar has made 21 insider trades between 2012-2024, according to the Form 4 filled with the SEC. Most recently he sold 125,000 units of SUPN stock worth $4,536,250 on 8 Nov 2024.
The largest trade he's ever made was exercising 192,000 units of SUPN stock on 8 Aug 2022. As of 8 Nov 2024 he still owns at least 926,172 units of SUPN stock.